Reconstructing disease. Finding what keeps it alive.
AnnieGuard is a computational therapeutic-discovery company developing Biology-First Intelligence (BFI), a proprietary, disease-agnostic method for reconstructing disease architecture from complex biological evidence. By identifying candidate dependencies that may sustain disease, we translate biological complexity into testable therapeutic hypotheses.
Supported by Leading Innovation Programs
From Disease Reconstruction to Therapeutic Discovery
Disease Architecture Reconstruction
Reconstruct complex disease states from incomplete, heterogeneous biological evidence to distinguish supported mechanisms from downstream consequences and unresolved explanations.
Dependency Discovery
Identify candidate biological dependencies that may sustain disease, including shared vulnerabilities across patients with otherwise distinct molecular profiles.
Therapeutic Hypothesis Generation
Translate reconstructed dependencies into candidate therapeutic targets, pathways, and intervention strategies, prioritizing hypotheses suitable for experimental testing.
Functional Validation
Strategy
Design discriminating experiments to evaluate therapeutic selectivity, pathway response, and genetic dependency, with predefined criteria for advancing or rejecting hypotheses.
Therapeutic Program Development
Our objective is to advance experimentally supported vulnerabilities into therapeutic discovery programs with potential for pharmaceutical co-development, licensing, and further preclinical investigation.
Discovery Begins With Causal Reconstruction.
From complex biological evidence to reconstructed disease architecture and experimentally testable therapeutic hypotheses.
CR(𝓔, 𝓗) → (S, U, ΔE)
Evidence + competing explanations → supported biological structure + unresolved alternatives + next discriminating evidence.
